<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100127003210N19</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-10</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>“Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Chemotherapy “</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Anthracycline-Cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-01-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/44800</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple Individual Randomization with the Card in Two Groups A and B, in this Way a Number of Cards are selected as the first Intervention Group and the same Number in the second Intervention Group, then by merging the Cards together one Card is drawn and its Allocation is recorded and the Card is returned to the other Cards after it has been removed. The Cards are then re-merged and another Card is withdrawn. The Process continues until a Random Sequence Sample Size is reached, Blinding description: Double blinding will be done for the Intervention.Groups will be designated as A and B, so the Principle Investigator, Outcome Assessor and Data Analyzer will not know how Patients are assigned.</study_design>
      <phase>3</phase>
      <hc_freetext>Patient with breast cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Eligible patients will receive: Triple Standard of Care Regimen [Aprepitant Capsule (125 mg PO OD on day 1, 80 mg OD on days 2-3), Granisetron (1 mg IV only on day 1), Dexametason (12 mg IV only on day 1)] and Mirtazapine Tablet (15 mg PO OD on days 1-4). The first Day of Chemotherapy begins Half an Hour to an Hour before Chemotherapy. Intervention 2: Intervention group 2: Eligible Patients will receive Triple Standard of Care Regimen [Aprepitant Capsule (125 mg PO OD on Day 1, 80 mg OD on Days 2-3), Granisetron (1 mg IV only on Day 1), Dexametason (12 mg IV only on Day 1)] and Olanzapine Tablet (10mg PO OD on Days 1-4). The first Day of Chemotherapy begins Half an Hour to an Hour before Chemotherapy. In Patients at Risk of Sedation, the Dose of Olanzapine is considered to be 5 mg.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is اطلاعات محرمانه است</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maria Tavakoli-Ardakani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti School of Pharmacy, Niayesh Highway, Valiasr Ave, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1991953381</zip>
        <telephone>+98 21 8820 0085</telephone>
        <email>Mariatavakoli@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maria Tavakoli-Ardakani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti School of Pharmacy, Niayesh Highway,Valiasr Ave, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1991953381</zip>
        <telephone>+98 21 8820 0085</telephone>
        <email>Mariatavakoli@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with Newly Diagnosed Breast Cancer
Receiving Anthracycline-Cyclophosphamide Chemotherapy Regimen in the adjuvant Setting for at least Two consecutive Cycles
Patients aged 18 to 65
Written Informed Consent
The Patient is able to read and understand the Questionnaires used in the Study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>A History of Allergy to Mirtazapine or Olanzapine
Patient with History of Dementia, peptic Ulcer, myocardial Infarction, Seizure, Arrhythmia, Glaucoma, and bipolar Disorder
Concomitant use of any Drug with Class X and D Interaction with the Drugs studied
Increased basal Creatinine (SrCr ≥ 1.5) or AST or ALT ≥ 3ULN
Brain Metastasis or Metastases with gastrointestinal Obstruction
Having Nausea and Vomiting within 24 hours prior to Chemotherapy
Patients with Disabilities taking oral Medications
On chronic antiemetic Therapy (e.g.Metoclopramide); on long Term use of systemic Steroids prior to Chemotherapy
Uncontrolled Diabetes
The Patient has a History of any Illness that, in the Opinion of the Investigator, might confound the Results of the Study or pros unwarranted Risk</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50.919</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of unspecified site of unspecified female breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Eligible patients will receive: Triple Standard of Care Regimen [Aprepitant Capsule (125 mg PO OD on day 1, 80 mg OD on days 2-3), Granisetron (1 mg IV only on day 1), Dexametason (12 mg IV only on day 1)] and Mirtazapine Tablet (15 mg PO OD on days 1-4). The first Day of Chemotherapy begins Half an Hour to an Hour before Chemotherapy.</i_keyword>
      <i_keyword>Intervention group 2: Eligible Patients will receive Triple Standard of Care Regimen [Aprepitant Capsule (125 mg PO OD on Day 1, 80 mg OD on Days 2-3), Granisetron (1 mg IV only on Day 1), Dexametason (12 mg IV only on Day 1)] and Olanzapine Tablet (10mg PO OD on Days 1-4). The first Day of Chemotherapy begins Half an Hour to an Hour before Chemotherapy. In Patients at Risk of Sedation, the Dose of Olanzapine is considered to be 5 mg.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of Nausea in the Group receiving Mirtazapine. Timepoint: During the Acute Phase [0-24 hours after chemotherapy (CT)], the Delayed (24-120 hours after CT) and the overall (0-120 hours after CT) phases for two CT cycles (each cycle is 21 ‏days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</prim_outcome>
      <prim_outcome>Severity of Nausea in the Group receiving Olanzapine. Timepoint: During the Acute Phase [0-24 hours after chemotherapy (CT)], the Delayed (24-120 hours after CT) and the overall (0-120 hours after CT) phases for two CT cycles (each cycle is 21 ‏days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</prim_outcome>
      <prim_outcome>Comparison of the Severity of Nausea in Two Groups receiving Mirtazapine and Olanzapine. Timepoint: During the Acute Phase [0-24 hours after chemotherapy (CT)], the Delayed (24-120 hours after CT) and the overall (0-120 hours after CT) phases for two CT cycles (each cycle is 21 ‏days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</prim_outcome>
      <prim_outcome>Severity of Vomiting in the Group receiving Mirtazapine. Timepoint: During the Acute Phase [0-24 hours after chemotherapy (CT)], the Delayed (24-120 hours after CT) and the overall (0-120 hours after CT) phases for two CT cycles (each cycle is 21 ‏days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</prim_outcome>
      <prim_outcome>Severity of Vomiting in the Group receiving Olanzapine. Timepoint: During the Acute Phase [0-24 hours after chemotherapy (CT)], the Delayed (24-120 hours after CT) and the overall (0-120 hours after CT) phases for two CT cycles (each cycle is 21 ‏days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</prim_outcome>
      <prim_outcome>‏Comparison of the Severity of Vomiting in Two Groups receiving Mirtazapine and Olanzapine. Timepoint: During the Acute Phase [0-24 hours after chemotherapy (CT)], the Delayed (24-120 hours after CT) and the overall (0-120 hours after CT) phases for two CT cycles (each cycle is 21 ‏days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comparison of The Quality of Life in Two Groups receiving Mirtazapine and Olanzapine. Timepoint: 120 Hours after Initiation of Chemotherapy. Method of measurement: 18-item Functional Living Index-Emesis (FLIE) Questionnaire.</sec_outcome>
      <sec_outcome>Severity of adverse Events in the Group receiving Mirtazapine. Timepoint: ‏During the Acute Phase [0-24 Hours after Chemotherapy (CT)], the Delayed (24-120 Hours after CT) and the Overall (0-120 Hours after CT) Phases for Two CT Cycles (each Cycle is 21 ‏Days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</sec_outcome>
      <sec_outcome>Severity of adverse Events in The Group receiving Olanzapine. Timepoint: During the Acute Phase [0-24 Hours after Chemotherapy (CT)], the Delayed (24-120 Hours after CT) and the Overall (0-120 Hours after CT) Phases for Two CT Cycles (each Cycle is 21 ‏Days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</sec_outcome>
      <sec_outcome>Comparison of the Severity of adverse Events in Two Groups receiving Mirtazapine and Olanzapine. Timepoint: During the Acute Phase [0-24 Hours after Chemotherapy (CT)], the Delayed (24-120 Hours after CT) and the Overall (0-120 Hours after CT) Phases for Two CT Cycles (each Cycle is 21 ‏Days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</sec_outcome>
      <sec_outcome>Comparison of the Severity of Somnolence in Two Groups receiving Mirtazapine and Olanzapine. Timepoint: During the Acute Phase [0-24 Hours after Chemotherapy (CT)], the Delayed (24-120 Hours after CT) and the Overall (0-120 Hours after CT) Phases for Two CT Cycles (each Cycle is 21 ‏Days). Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</sec_outcome>
      <sec_outcome>Comparison of the Severity of Anorexia in Two Groups receiving Mirtazapine and Olanzapine. Timepoint: During the Acute Phase [0-24 Hours after Chemotherapy (CT)], the Delayed (24-120 Hours after CT) and the Overall (0-120 Hours after CT) Phases for Two CT Cycles (each Cycle is 21 ‏Days. Method of measurement: National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-11-04</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti School of Pharmacy, Niayesh Highway, Valiasr Ave, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
